BRPI0910702A2 - modified factor ix polypeptides and uses thereof - Google Patents

modified factor ix polypeptides and uses thereof

Info

Publication number: BRPI0910702A2
Authority: BR; Brazil
Prior art keywords: polypeptides; modified factor; factor; modified
Prior art date: 2008-04-16

Application number

BRPI0910702A

Other languages

Portuguese (pt)

Inventor

Alan Brooks

Chandra Patel

John E Murphy

Kornelia Kirchner

Marian Seto

Ulrich Haupts

Uwe Gritzan

Xiaoqiao Jiang

Original Assignee

Bayer Healthcare Llc

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-16

Filing date

2009-04-16

Publication date

2016-07-05

2009-04-16 Application filed by Bayer Healthcare Llc, Bayer Schering Pharma Ag filed Critical Bayer Healthcare Llc

2016-07-05 Publication of BRPI0910702A2 publication Critical patent/BRPI0910702A2/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0910702A 2008-04-16 2009-04-16 modified factor ix polypeptides and uses thereof BRPI0910702A2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12456708P	2008-04-16	2008-04-16
US4596108P	2008-04-17	2008-04-17
PCT/US2009/040813 WO2009137254A2 (en)	2008-04-16	2009-04-16	Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI0910702A2 true BRPI0910702A2 (en)	2016-07-05

Family

ID=41265284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0910702A BRPI0910702A2 (en)	2008-04-16	2009-04-16	modified factor ix polypeptides and uses thereof

Country Status (17)

Country	Link
EP (1)	EP2288622A4 (en)
JP (1)	JP2011517951A (en)
KR (1)	KR20110005862A (en)
CN (1)	CN102083856A (en)
AU (1)	AU2009244633A1 (en)
BR (1)	BRPI0910702A2 (en)
CA (1)	CA2721683A1 (en)
CO (1)	CO6311000A2 (en)
CR (1)	CR11737A (en)
DO (1)	DOP2010000311A (en)
EC (1)	ECSP10010551A (en)
IL (1)	IL208718A0 (en)
MX (1)	MX2010011345A (en)
RU (1)	RU2010146387A (en)
SG (1)	SG189790A1 (en)
SV (1)	SV2010003704A (en)
WO (1)	WO2009137254A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8383388B2 (en) *	2006-06-19	2013-02-26	Catalyst Biosciences, Inc.	Modified coagulation factor IX polypeptides and use thereof for treatment
US20110154516A1 (en) *	2007-10-15	2011-06-23	Stafford Darrel W	Human factor ix variants with an extended half life
DK3581650T3 (en) *	2008-09-15	2023-03-13	Uniqure Biopharma B V	FACTOR IX POLYPEPTIDE MUTANT, USE THEREOF AND A PROCEDURE FOR MANUFACTURE THEREOF
CN103140237A (en)	2010-07-09	2013-06-05	比奥根艾迪克依蒙菲利亚公司	Factor ix polypeptides and methods of use thereof
AU2013204511B2 (en) *	2010-11-03	2016-03-17	Gc Biopharma Corp.	Modified factor ix polypeptides and uses thereof
TWI557135B (en) *	2010-11-03	2016-11-11	介控生化科技公司	Modified ninth factor multi-peptide and use thereof
CA2838833A1 (en)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof
EP2737311B1 (en)	2011-07-25	2020-12-02	Bioverativ Therapeutics Inc.	Assays to monitor bleeding disorders
JP5967631B2 (en) *	2012-04-27	2016-08-10	学校法人日本大学	Treatment for epithelial and endothelial damage
US10001495B2 (en)	2012-07-25	2018-06-19	Bioverativ Therapeutics Inc.	Blood factor monitoring assay and uses thereof
HK1213521A1 (en)	2012-09-25	2016-07-08	Bioverativ Therapeutics Inc.	Methods of using fix polypeptides
US10391152B2 (en)	2012-10-18	2019-08-27	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
US10717965B2 (en)	2013-01-10	2020-07-21	Gloriana Therapeutics, Inc.	Mammalian cell culture-produced neublastin antibodies
RS64664B1 (en)	2013-02-15	2023-11-30	Bioverativ Therapeutics Inc	Optimized factor viii gene
US10588949B2 (en)	2013-03-15	2020-03-17	Bioverativ Therapeutics Inc.	Factor IX polypeptide formulations
HUE057005T2 (en)	2013-09-25	2022-04-28	Bioverativ Therapeutics Inc	Column virus inactivation procedures
EP3065769A4 (en)	2013-11-08	2017-05-31	Biogen MA Inc.	Procoagulant fusion compound
US10325687B2 (en)	2013-12-06	2019-06-18	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
US20160289633A1 (en)	2013-12-20	2016-10-06	Biogen Ma Inc.	Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
SG10201808249VA (en)	2014-03-24	2018-10-30	Bioverativ Therapeutics Inc	Lyophilized factor ix formulations
US11008561B2 (en)	2014-06-30	2021-05-18	Bioverativ Therapeutics Inc.	Optimized factor IX gene
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
BR112018002150A2 (en)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	factor ix fusion proteins and methods of manufacturing and using them
HRP20221089T1 (en)	2016-02-01	2022-11-25	Bioverativ Therapeutics Inc.	Optimized factor viii genes
CN105695616A (en) *	2016-04-22	2016-06-22	王冬国	Analysis marker for diagnosing thyroid cancer and application thereof
IL308416B2 (en)	2016-12-02	2025-08-01	Bioverativ Therapeutics Inc	Methods for treating hemophilic arthritis using chimeric blood clotting factors
CR20190389A (en)	2017-01-31	2019-11-26	Bioverativ Therapeutics Inc	Factor ix fusion proteins and methods of making and using same
FR3069540B1 (en)	2017-07-28	2019-09-13	Universite Claude Bernard Lyon 1	MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
TWI904068B (en)	2017-08-09	2025-11-11	美商生物化學醫療公司	Nucleic acid molecules and uses thereof
BR112020006149A2 (en)	2017-09-27	2020-10-20	Sigilon Therapeutics, Inc.	manipulated active cell, implantable element, and pharmaceutical composition.
US11491212B1 (en)	2017-09-27	2022-11-08	Catalyst Biosciences, Inc.	Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
WO2019195056A1 (en)	2018-04-04	2019-10-10	Sigilon Therapeutics, Inc.	Methods, compositions, and implantable elements comprising stem cells
US12161760B2 (en)	2018-04-04	2024-12-10	Sigilon Therapeutics, Inc.	Implantable particles and related methods
BR112020022164A2 (en)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	methods of treating hemophilia a
CA3108799A1 (en)	2018-08-09	2020-02-13	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof for non-viral gene therapy
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
UY38389A (en)	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en)	2018-10-26	2020-04-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A high-yield perfusion-based transient gene expression bioprocess
CA3136720A1 (en)	2019-04-17	2020-10-22	Codiak Biosciences, Inc.	Compositions of exosomes and aav
WO2021067389A1 (en)	2019-09-30	2021-04-08	Bioverativ Therapeutics Inc.	Lentiviral vector formulations
WO2021154414A2 (en)	2020-01-29	2021-08-05	Catalyst Biosciences, Inc.	Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4171657A1 (en)	2020-06-24	2023-05-03	Bioverativ Therapeutics Inc.	Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
US11670855B2 (en)	2021-02-24	2023-06-06	Bluehalo, Llc	System and method for a digitally beamformed phased array feed
JP2025534667A (en)	2022-10-11	2025-10-17	シギロンセラピューティクス，インコーポレイテッド	Engineered cells and implantable elements for disease treatment
EP4602155A1 (en)	2022-10-11	2025-08-20	Sigilon Therapeutics, Inc.	Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2638643B1 (en) *	1988-11-09	1991-04-12	Transgene Sa	DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
WO1999003496A1 (en) *	1997-07-21	1999-01-28	The University Of North Carolina At Chapel Hill	Factor ix antihemophilic factor with increased clotting activity
BR0212035A (en) *	2001-09-04	2004-08-03	Merck Patent Gmbh	Modified ix factor
KR20060034216A (en) *	2003-04-09	2006-04-21	넥타르 테라퓨틱스	Hemophilia Treatment by Inhalation of Coagulation Factors
US20060040856A1 (en) *	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
WO2005055950A2 (en) *	2003-12-03	2005-06-23	Neose Technologies, Inc.	Glycopegylated factor ix
US8383388B2 (en) *	2006-06-19	2013-02-26	Catalyst Biosciences, Inc.	Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) *	2007-01-09	2010-04-20	Shu-Wha Lin	Recombinant human factor IX and use thereof

2009
- 2009-04-16 KR KR1020107025567A patent/KR20110005862A/en not_active Ceased
- 2009-04-16 WO PCT/US2009/040813 patent/WO2009137254A2/en not_active Ceased
- 2009-04-16 JP JP2011505204A patent/JP2011517951A/en active Pending
- 2009-04-16 BR BRPI0910702A patent/BRPI0910702A2/en not_active IP Right Cessation
- 2009-04-16 EP EP09743241A patent/EP2288622A4/en not_active Withdrawn
- 2009-04-16 MX MX2010011345A patent/MX2010011345A/en not_active Application Discontinuation
- 2009-04-16 CA CA2721683A patent/CA2721683A1/en not_active Abandoned
- 2009-04-16 CN CN2009801227842A patent/CN102083856A/en active Pending
- 2009-04-16 RU RU2010146387/10A patent/RU2010146387A/en not_active Application Discontinuation
- 2009-04-16 AU AU2009244633A patent/AU2009244633A1/en not_active Abandoned
- 2009-04-16 SG SG2013028790A patent/SG189790A1/en unknown
2010
- 2010-10-14 IL IL208718A patent/IL208718A0/en unknown
- 2010-10-15 CO CO10128682A patent/CO6311000A2/en active IP Right Grant
- 2010-10-15 DO DO2010000311A patent/DOP2010000311A/en unknown
- 2010-10-15 SV SV2010003704A patent/SV2010003704A/en unknown
- 2010-10-15 CR CR11737A patent/CR11737A/en not_active Application Discontinuation
- 2010-10-15 EC EC2010010551A patent/ECSP10010551A/en unknown

Also Published As

Publication number	Publication date
CO6311000A2 (en)	2011-08-22
WO2009137254A2 (en)	2009-11-12
IL208718A0 (en)	2010-12-30
DOP2010000311A (en)	2011-02-28
WO2009137254A3 (en)	2010-01-14
AU2009244633A1 (en)	2009-11-12
CN102083856A (en)	2011-06-01
SV2010003704A (en)	2011-02-21
ECSP10010551A (en)	2010-11-30
RU2010146387A (en)	2012-05-27
EP2288622A2 (en)	2011-03-02
CA2721683A1 (en)	2009-11-12
MX2010011345A (en)	2011-02-23
CR11737A (en)	2011-02-07
KR20110005862A (en)	2011-01-19
SG189790A1 (en)	2013-05-31
JP2011517951A (en)	2011-06-23
EP2288622A4 (en)	2012-04-18

Publication	Publication Date	Title
BRPI0910702A2 (en)	2016-07-05	modified factor ix polypeptides and uses thereof
BR112012002072A2 (en)	2016-11-08	modified factor ix polypeptides and uses thereof
BRPI0911060A2 (en)	2015-10-13	factor vii polypeptides that are modified and uses thereof
BR112012006501A2 (en)	2016-08-16	polypeptides and uses thereof
BRPI0912198A2 (en)	2019-09-24	anti-fn14 antibodies and uses thereof
BRPI0922790A2 (en)	2018-11-06	sparc-binding peptides and uses thereof
BRPI0920927A2 (en)	2019-09-24	azaquinolinone derivatives and uses thereof
PT2531206T (en)	2017-09-05	CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES OF THE SAME
BRPI0916515A2 (en)	2018-03-13	modified bovine g-csf polypeptide and uses thereof
BRPI0908906A2 (en)	2019-09-24	heterocyclic compounds and their uses
BRPI0819909A2 (en)	2017-12-19	antimesothelin antibodies and their uses
BRPI1009455A2 (en)	2016-03-01	anti-c40 antibodies and uses thereof
BRPI0810172A2 (en)	2014-10-14	MODIFIED Factor VII polypeptides and their uses
SMT201600335B (en)	2016-11-10	PROTEINS BINDING HETERODIMERS AND THEIR USES
BR112012003709A2 (en)	2016-04-05	heterocyclic compounds and their uses
BRPI0913656A2 (en)	2019-09-24	radioisotope-labeled anti-cdh3 antibodies and uses thereof
BRPI0923283A2 (en)	2017-06-06	therapeutic peptide conjugates and uses thereof
DK3663399T3 (en)	2022-03-21	Modified factor IX polypeptides and uses thereof
BRPI0915142A2 (en)	2016-02-16	polypeptides, nucleic acid and uses thereof
BRPI0907231A2 (en)	2019-09-24	pyrrolpyrimidines and pyrrolpyridines
BRPI0817312A2 (en)	2015-03-17	Phageru polynucleotides and polypeptides and uses thereof
BRPI0922708A2 (en)	2018-11-06	minihepidine peptides and methods of use thereof
BRPI0914682A2 (en)	2015-10-20	heteroaryl compounds and uses thereof
BRPI1011404A2 (en)	2016-03-15	mutants and their uses
BRPI0905715A2 (en)	2015-07-14	Pharmaceutical Composition and Component Kit

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]